Please provide your email address to receive an email when new articles are posted on . Lower Schirmer’s test score correlated with increased corneal staining and more severe disease burden among ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the designation of Schirmer test, a measure of tear production, as the sole primary endpoint in ...
Reproxalap Statistically Superior to Vehicle for Both Prespecified Primary Endpoints of Schirmer Test (p=0.0001) and ≥10 mm Schirmer Test Responder Proportions (p<0.0001) TRANQUILITY-2 Results May ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The reactive ...
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — In this Healio Video Perspective from the American Society of Cataract and Refractive Surgery ...
Aldeyra Therapeutics, Inc. ALDX announced positive data from the vehicle-controlled crossover clinical study which evaluated its investigational product candidate, 0.25% reproxalap ophthalmic solution ...
Aldeyra Therapeutics’ late-study primary endpoint switch has paid off. Weeks after disclosing the change to its dry eye disease phase 3 trial, the biotech has reported a hit against the new primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback